Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Magle Chemoswed via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Språk
Typ
Språk
Typ
2025-06-24 11:40:00
Magle Biopolymers Launches Dextran Webshop
Online Access to High Grade Dextran Products
2025-06-11 09:00:00
Magle Group Partners with Skåne Stadsmission to Support Community Initiatives
Magle Group is proud to announce a new partnership with Skåne Stadsmission, a Swedish non-profit organization dedicated to improving the lives of individuals
2025-01-07 08:00:00
Magle Group Announces Publication of prospective HepaStar Trial Results Highlighting Promising Outcomes for DSM-TACE in Hepatocellular Carcinoma
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) announces the publication of the final results of the prospective HepaStar trial, a multicenter observational trialevaluating the safety and effectiveness of EmboCept® S DSM 50 µm in the treatment of unresectable hepatocellular carcinoma (HCC)
2024-07-01 08:00:00
Magle PharmaCept Expands Distribution Agreement to Include Strategic European Territories
Magle PharmaCept, a subsidiary of Magle Group, is pleased to announce the extension of its distribution agreement with its key distributor in the wound care field. The expanded agreement now includes strategic European territories, enhancing our reach and reinforcing our commitment to providing innovative wound care solutions across the region
2024-07-01 08:00:00
Magle PharmaCept utökar distributionsavtalet till att omfatta strategiska europeiska territorier
Magle PharmaCept, ett dotterbolag till Magle Group, är glada att meddela att distributionsavtalet med vår nyckeldistributör inom sårvårdsområdet har utökats. Det utökade avtalet omfattar nu strategiska europeiska territorier, vilket ökar vår räckvidd och stärker vårt engagemang för att tillhandahålla innovativa sårvårdslösningar över hela regionen
2024-06-24 08:26:00
Magle Chemoswed Awarded GMP License to Expand Offerings in Solid State Chemistry Laboratory Services
Magle Chemoswed, a wholly owned subsidiary of Magle Group, is proud to announce that it has been awarded a Good Manufacturing Practice (GMP) license to broaden its already existing GMP offerings to include laboratory services in the field of solid state chemistry
2024-06-17 07:00:00
Magle Group Announces Appointment of Distributor for SmartPAN® in Austria
Magle Group, through its subsidiary Magle PharmaCept, is pleased to announce the appointment of a new distributor for SmartPAN® in Austria
2024-06-17 07:00:00
Magle Group utser distributör för SmartPAN® i Österrike.
Magle Group, genom sitt dotterbolag Magle PharmaCept, har nöjet att meddela utnämningen av en ny distributör för SmartPAN® i Österrike
2024-06-03 08:00:00
Magle Group Announces Appointment of Distributor for SmartPAN® in Singapore
Magle Group, through its subsidiary Magle PharmaCept, is excited to announce the appointment of a new distributor for SmartPAN® in Singapore. This strategic partnership represents a pivotal step in our efforts to introduce SmartPAN® to the Asian market, underlining our commitment to improving pancreatic surgery outcomes globally
2024-06-03 08:00:00
Magle Group tillkännager utnämningen av distributör för SmartPAN® i Singapore
Magle Group, genom sitt dotterbolag Magle PharmaCept, är glada att meddela utnämningen av en ny distributör för SmartPAN® i Singapore. Detta strategiska partnerskap representerar ett avgörande steg i våra ansträngningar att introducera SmartPAN® på den asiatiska marknaden, vilket understryker vårt engagemang för att förbättra resultaten av bukspottkörtelkirurgi globalt
2023-06-28 11:05:00
Magle Group initiates collaboration with leading German university hospital to explore synergies between EmboCept® S DSM 50 µm and immunotherapies
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy
2023-05-16 11:00:00
Magle Group broadens its project portfolio through in-licensing of clinical-stage cancer vaccine candidate from CHOSA Oncology AB
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has in-licensed the clinical-stage therapeutic cancer vaccine candidate onilcamotide from Chosa Oncology AB. Magle Group plans to further develop onilcamotide by use of its proprietary degradable starch microspheres (DSM) technology. The company sees a future potential to combine onilcamotide treatment...
2021-02-27 10:01:00
Magle Chemoswed congratulates Oncopeptides
Magle Chemoswed congratulates everyone at Oncopeptides for receiving FDA approval of PEPAXTO®. We are proud to have been chosen by Oncopeptides as a development and manufacturing partner for the active pharmaceutical substance. It has been a great pleasure to support Oncopeptides and supply development and manufacturing services around the active pharmaceutical substance through all phases of the...
2020-07-07 09:45:00
Encapsulation of pharmaceutical proteins in starch microparticles project
Magle Chemoswed joins collaboration with Malmö University on exciting new project. The project will focus on the use of the Company technology platform as a novel delivery system in conjunction with proteins. Protein-based therapeutics are becoming increasingly popular in medicine. Compared to low molecular drugs, they are more specific, cause fewer side effects and are environmentally friendly. ...